Loading...
The combination of vemurafenib and procaspase-3 activation is synergistic in mutant BRAF melanomas
The development of vemurafenib resistance limits the long-term efficacy of this drug for treatment of metastatic melanomas with the (V600E)BRAF mutation. Inhibition of downstream MAPK signaling with vemurafenib induces apoptotic cell death mediated by caspase-3, suggesting that addition of a procasp...
Na minha lista:
| Udgivet i: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4975653/ https://ncbi.nlm.nih.gov/pubmed/27297867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0025 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|